Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Florida Health
Jacksonville, Florida, United States
- University of Illinois at Chicago
Chicago, Illinois, United States
- the Ohio State University
Columbus, Ohio, United States
- Oregon Health & Science University
Portland, Oregon, United States
- Medical University of South Carolina
Charleston, South Carolina, United States
- the University of Texas at Austin
Austin, Texas, United States
- Texas Tech University Health Sciences Center
El Paso, Texas, United States
- Brooke Army Medical Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Sept 2018
- Primary completion
- 1 Dec 2024
- Completion
- 1 Dec 2024
- Last update posted
- 20 Nov 2025
- Registered enrollment
- 34
- Registry id
- NCT03624517
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.